Clinical trial

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

NCT04743479

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DIAGNOSTIC_TEST · Unmapped registry intervention high-resolution MRI/CT examinations Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2020-12-01

PhaseN/A

Conditions

Pancreatic Cancerverified · MONDO: malignant pancreatic neoplasm

Diabetesverified · MONDO: diabetes mellitus

Familial Pancreatic Cancerverified · MONDO: familial pancreatic carcinoma

Pancreatic Cystic Neoplasmunresolved

Chronic Pancreatitisverified · MONDO: chronic pancreatitis

Hereditary Pancreatitisverified · MONDO: hereditary chronic pancreatitis

Interventions

high-resolution MRI/CT examinationsDIAGNOSTIC_TEST

Sponsors & collaborators

Changhai Hospitallead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04743479 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.